TMS 2026: HSDD biopsychosocial approach, night sweats red flags, misread WHI data

Thank you for visiting the Contemporary OB/GYN website. Take a look at some of our top expert interviews and coverage from The Menopause Society 2026 Annual Meeting (Tuesday, October 20, to Saturday, October 24, 2026, in San Diego, California) and click on each link to read and watch anything you may have missed.

Pooled OASIS data: 66.9% achieve ≥50% VMS reduction with elinzanetant

Elinzanetant reduced moderate-to-severe vasomotor symptom (VMS) frequency by ≥50% in 66.9% of US-postmenopausal participants, compared with 40.5% of those receiving placebo, from weeks 4 to 12, according to a pooled analysis of the phase 3 OASIS-1 (NCT05042362) and OASIS-2 (NCT05099159) trials presented at the meeting.

Click here for full study details.

A biopsychosocial approach to hypoactive sexual desire disorder

Low libido meets criteria for hypoactive sexual desire disorder (HSDD) only when it causes clinically significant distress, and identifying it requires an evaluation across medical, relational, psychological, and sociocultural domains, according to Holly N. Thomas, MD, MS, associate professor of medicine at the University of Pittsburgh Medical Center in Pennsylvania.

Click here to watch the full discussion with Holly N. Thomas, MD, MS.

Stephanie Faubion, MD, on the first menopause therapy discussion

Menopause management should begin with a clear understanding of a patient's treatment goals, which then guide the choice between hormonal and nonhormonal therapy, according to Stephanie S. Faubion, MD, MBA, FACP, MSCP, IF, medical director of The Menopause Society, who discussed choosing between the neurokinin 3 receptor antagonists fezolinetant and elinzanetant, liver monitoring, and follow-up.

Click here to watch the full discussion with Stephanie S. Faubion, MD.

Red flags that point beyond menopause in patients with night sweats

Night sweats in a midlife patient who also reports hot flashes usually reflect menopause, but late recurrence after stopping hormone therapy, high-risk features such as fever, lymphadenopathy, or weight loss, and persistence despite treatment should prompt evaluation for other causes, according to Cheryl Cox Kinney, MD, FACOG, MSCP, director of the Dr. Cheryl Kinney Center for Female Health and Hormone Disorders in Dallas, Texas, and president of The Menopause Society.

Click here to watch the full discussion with Cheryl Cox Kinney, MD, FACOG, MSCP.

Susan Reed, MD, on the benefits of the MsFLASH clinical trials network

Pooled data from the NIH-funded MsFLASH clinical trials network showed that nonhormonal therapies, including the SSRI and SNRI agents escitalopram and venlafaxine, were similar in efficacy to low-dose oral estradiol 0.5 mg for hot flashes, according to Susan Reed, MD, MPH, MS, professor emeritus of obstetrics and gynecology at the University of Washington in Seattle.

Click here to watch the full discussion with Susan Reed, MD, MPH, MS.

How misread WHI data reshaped menopause care and training

Misinterpretation of the 2002 Women's Health Initiative (WHI) results on estrogen plus progestin sidelined hormone therapy and eroded menopause education in residency training, according to Mary Jane Minkin, MD, FACOG, who said programs are now working to catch up as interest in menopause care surges.

Click here to watch the full discussion with Mary Jane Minkin, MD, FACOG.

For more of our coverage, click here.